Article (Scientific journals)
Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel; Bruyère, Olivier; Cooper, Cyrus et al.
2016In Drugs and Aging, 33 (2), p. 75-85
Peer Reviewed verified by ORBi
 

Files


Full Text
Diacerein. Benefits, risks and place in the management of osteoarthritis. An opinion based report from the ESCEO.pdf
Publisher postprint (649.83 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated
Disciplines :
Public health, health care sciences & services
General & internal medicine
Author, co-author :
Pavelka, Karel
Bruyère, Olivier  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cooper, Cyrus
Kanis, John A
Leeb, Burkhard F.
Maheu, Emmanuel
Martel-Pelletier, Johanne
Monfort, Jordi
Pelletier, Jean-Pierre
Rizzoli, René
Reginster, Jean-Yves  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Publication date :
February 2016
Journal title :
Drugs and Aging
ISSN :
1170-229X
eISSN :
1179-1969
Publisher :
Adis International, Auckland, New Zealand
Volume :
33
Issue :
2
Pages :
75-85
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, a Belgian not-for-profit organisation.
Available on ORBi :
since 11 February 2016

Statistics


Number of views
82 (13 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
115
Scopus citations®
without self-citations
108
OpenCitations
 
88

Bibliography


Similar publications



Contact ORBi